Latest Content

George Sakoulas, MD, discusses how transitioning pneumonia patients from IV to oral therapy after 3 to 4 days of clinical stability supports effective 7-day treatment courses, while patients who are immunocompromised and those with Pseudomonas infections require individualized, extended management.

Sustained HIV/syphilis elimination of mother-to-child transmission (EMTCT) since 2019 and new hepatitis B validation reflect high antenatal screening, >95% HBV birth-dose coverage, and integrated maternal–child health services.

The 2025 report from the WHO Global Antibiotic Resistance Surveillance System (GLASS) calls for urgent action against increasing threat of AMR. This is part 2 of 2-part coverage of the WHO Global Antibiotic Resistance Surveillance System Report 2025.

The Global Antimicrobial Resistance and Use Surveillance System (GLASS) of the WHO finds antibiotic resistance and the particular threat of resistant Gram-negative bacteria disproportionately prevalent in low- and middle-income countries. Here is part 1 of 2-part coverage of the WHO Global Antibiotic Resistance Surveillance Report.

This week, meet SIDP's president-elect, the connection between UTIs and meat, a COVID-19 vaccine alternative, and other highlights from IDWeek.

A new genomic study reveals that up to 18% of urinary tract infections (UTIs) in Southern California may stem from E coli strains transmitted through contaminated poultry and meat, disproportionately affecting residents of low-income neighborhoods.

Jesse Clark, MD, MSc, discusses a study’s subset preliminary findings looking at this form of PrEP in this patient population.

Ed J Kuijper, MD, PhD details who is at highest risk for rCDI, how to interpret NAAT–toxin results, and how to sequence fidaxomicin, vancomycin, and microbiota-based therapies.

Moderna’s investigational cytomegalovirus (CMV) vaccine, mRNA-1647, did not meet its primary endpoint in a phase 3 trial, leading the company to discontinue its congenital CMV program while continuing studies in transplant patients.

At IDWeek, the company reported promising phase 1/2 trial results for its shingles vaccine candidate Z-1018, demonstrating strong immune responses and favorable tolerability.

Cornelius Clancy, MD, discusses insights from the real-world clinical analysis of the US cohort of the PROVE study.

Lori Handy, MD, MSCE, emphasized that rebuilding public trust requires continuous engagement and a collective rethinking of medical communication.

Phase 3 results for tebipenem HBr suggest an oral carbapenem could provide an effective alternative to IV therapy for multidrug-resistant UTIs.